Cas:52263-23-7 (4-Oxocyclohexyl)acetic acid manufacturer & supplier

We serve Chemical Name:(4-Oxocyclohexyl)acetic acid CAS:52263-23-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

(4-Oxocyclohexyl)acetic acid

Chemical Name:(4-Oxocyclohexyl)acetic acid
CAS.NO:52263-23-7
Synonyms:4-oxocyclohexylacetic acid;RW2722;Cyclohexaneacetic acid, 4-oxo-;(4-Oxocyclohexyl)acetic acid
Molecular Formula:C8H12O3
Molecular Weight:156.179
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:327.5±15.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.484
PSA:54.37000
Exact Mass:156.078644
LogP:0.02

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4-oxocyclohexylacetic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(4-Oxocyclohexyl)acetic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(4-Oxocyclohexyl)acetic acid Use and application,RW2722 technical grade,usp/ep/jp grade.


Related News: AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment. (4-Oxocyclohexyl)acetic acid manufacturer AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer. (4-Oxocyclohexyl)acetic acid supplier AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment. (4-Oxocyclohexyl)acetic acid vendor Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. (4-Oxocyclohexyl)acetic acid factory If the drug is in a syrup form, then the excipient is the liquid that has been used to make it as such.